August 28, 2017 (San Diego, CA) – Suneva® Medical, Inc., renowned privately held aesthetics company, announces the appointment of Vince Ippolito to their esteemed Board of Directors.

Vince Ippolito has over 30 years of experience in the pharmaceuticals industry, including 20 years in dermatology and aesthetic medicine. He most recently served as the Chief Commercial Officer Executive Vice President of Anacor Pharmaceuticals until Sept 2017, where he was responsible for developing marketing and sales functions, as well as strategizing the company’s product portfolio. Previously, Mr. Ippolito was Executive Vice President and Chief Commercial Officer at Medicis, a leading dermatology and aesthetic medicine company, who brought Restylane and Dysport to Market in the US. Throughout his career, he has launched more than 20 brands in dermatology and aesthetic medicine. He took a leading role in two of the largest dermatology acquisitions in the past five years totaling $7.8 billion.

Mr. Ippolito holds a B.A. in Business Administration, Management, and Operations from the University of Wisconsin and a minor in East Asian Studies from Sophia University in Japan.
Preston Romm, Suneva’s President and Chief Executive Officer, said “Suneva is very excited to have Vince join our board. His experience and knowledge of the dermatology maket and specifically, the aesthetics market, is invaluable. The combination of Vince Ippolito and Dennis Condon on our board will help take Suneva to the next level.”
“I am thrilled to be a part of the Suneva Board. Preston Romm has assembled a team of highly seasoned Aesthetic professionals and I look forward to contributing to Sunevas growth and success” said Mr. Ippolito.

About Suneva Medical, Inc.
Suneva Medical is a privately‐held aesthetics company focused on developing, manufacturing and commercializing novel, differentiated products for the aesthetic markets. The innovative aesthetics leader markets Bellafill®, the only dermal filler on the market that is approved by the U.S. Food and Drug Administration for the correction of nasolabial folds and moderate to severe, atrophic, distensible facial acne scars on the cheek in patients over the age of 21 years old. The company markets Bellafill® in the U.S., Canada, Hong Kong, Korea and Mexico. For more information, visit